{"id":12519,"date":"2021-05-17T12:34:54","date_gmt":"2021-05-17T11:34:54","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=11345"},"modified":"2021-10-11T14:49:43","modified_gmt":"2021-10-11T13:49:43","slug":"webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/","title":{"rendered":"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021"},"content":{"rendered":"\n<p>This <a href=\"https:\/\/gardp.org\/news-resources\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents\/\" target=\"_blank\" rel=\"noreferrer noopener\">live webinar<\/a> including interactive Q&amp;A session will be broadcast on 27 May 2021 at 9:30-11:00 CEST. Find your time zone&nbsp;<a href=\"https:\/\/www.timeanddate.com\/worldclock\/converter.html?iso=20210527T073000&amp;p1=87\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a>.<\/p>\n\n\n\n<p><strong>Speakers:<\/strong><\/p>\n\n\n\n<ul><li>David Paterson, Director, University of Queensland Centre for Clinical Research (Australia)<\/li><li>Julie Marsh, Biostatistical Lead, Wesfarmers Centre of Vaccines and Infectious Diseases, University of Western Australia (Australia)<\/li><\/ul>\n\n\n\n<p><strong>Presentation 1: Overview of innovations in clinical trials of antimicrobial agents&nbsp;(David Paterson)<\/strong><\/p>\n\n\n\n<ul><li>The value proposition of clinical trial networks<\/li><li>What could MAMS, DOOR or PRACTical bring to clinical trials of antimicrobials?<\/li><li>Pros and cons of new clinical trial designs<\/li><\/ul>\n\n\n\n<p><strong>Presentation 2: Overview of adaptive trials in vaccines &amp; antimicrobial agents (Julie Marsh)<\/strong><\/p>\n\n\n\n<ul><li>Adaptive trials<\/li><li>Understanding the decision process for trial adaptations<\/li><li>Implementation challenges<\/li><li>Trial governance &amp; integrity<\/li><\/ul>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\n<p>If you have questions or comments, please let us know:&nbsp;<a href=\"mailto:revive@gardp.org\" target=\"_blank\" rel=\"noreferrer noopener\">revive@gardp.org<\/a>.<\/p>\n\n\n\n<p>Registration <a href=\"https:\/\/register.gotowebinar.com\/register\/1026166920370829582?source=GARDP\" target=\"_blank\" rel=\"noreferrer noopener\">on this link<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This live webinar including interactive Q&amp;A session will be broadcast on 27 May 2021 at 9:30-11:00 CEST. Find your time zone&nbsp;here. Speakers: David Paterson, Director, University of Queensland Centre for Clinical Research (Australia) Julie Marsh, Biostatistical Lead, Wesfarmers Centre of Vaccines and Infectious Diseases, University of Western Australia (Australia) Presentation 1: Overview of innovations in [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":12341,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[35],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021 - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-17T11:34:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-11T13:49:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"526\" \/>\n\t<meta property=\"og:image:height\" content=\"522\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021\",\"datePublished\":\"2021-05-17T11:34:54+00:00\",\"dateModified\":\"2021-10-11T13:49:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\"},\"wordCount\":147,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg\",\"articleSection\":[\"Ev\u00e8nements &amp; Colloques\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\",\"name\":\"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg\",\"datePublished\":\"2021-05-17T11:34:54+00:00\",\"dateModified\":\"2021-10-11T13:49:43+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg\",\"width\":526,\"height\":522,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Events &amp; Conferences\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/events-conferences\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/","og_locale":"en_GB","og_type":"article","og_title":"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-05-17T11:34:54+00:00","article_modified_time":"2021-10-11T13:49:43+00:00","og_image":[{"width":526,"height":522,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021","datePublished":"2021-05-17T11:34:54+00:00","dateModified":"2021-10-11T13:49:43+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/"},"wordCount":147,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg","articleSection":["Ev\u00e8nements &amp; Colloques"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/","name":"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg","datePublished":"2021-05-17T11:34:54+00:00","dateModified":"2021-10-11T13:49:43+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Essai-clinique.jpg","width":526,"height":522,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/evenements-colloques\/webinar-new-clinical-trial-designs-for-evaluation-of-antimicrobial-agents-27-may-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"Events &amp; Conferences","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/events-conferences\/"},{"@type":"ListItem","position":4,"name":"Webinar: New clinical trial designs for evaluation of antimicrobial agents, 27 May 2021"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-28 12:14:39","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/12519"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=12519"}],"version-history":[{"count":2,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/12519\/revisions"}],"predecessor-version":[{"id":17829,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/12519\/revisions\/17829"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/12341"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=12519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=12519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=12519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}